{"text":[[{"start":10.14,"text":"Shares of US vaccine-maker Moderna more than doubled in pre-market trading after the company reported successful results for a melanoma cancer vaccine that is being developed with Merck."}],[{"start":21.52,"text":"Moderna on Wednesday said the therapy delivered the first positive outcome in a late-stage trial for an mRNA cancer vaccine."}],[{"start":28.88,"text":"“Today’s results represent a landmark moment for adjuvant melanoma treatment,” said Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia."}],[{"start":41.14,"text":"The results of the trial sent Moderna’s share price to its highest level since 2024 in pre-market trading."}],[{"start":48.14,"text":"But even with the rise, Moderna’s shares would still be worth less than one-third of the levels hit during the company’s heyday in 2021 amid the development of the coronavirus vaccine."}],[{"start":58.84,"text":"The group became a corporate hero during the pandemic as it rushed to develop a vaccine against Covid-19. But its fortunes have since turned as it faces weaker demand for the coronavirus jab."}],[{"start":72.075,"text":"Shares in fellow US drugmaker Merck rose 6 per cent in pre-market trading."}],[{"start":75.58,"text":"This is a developing story."}],[{"start":82.38,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1787141547_6397.mp3"}